Raras
Buscar doenças, sintomas, genes...
Distrofia muscular, congênita
ORPHA:97242CID-11 · 8C70.6DOENÇA RARA

Uma distrofia muscular caracterizada por músculos com tônus reduzido (ficam mais moles), fraqueza muscular progressiva e desgaste dos músculos (atrofia), articulações que ficam presas de forma incomum, rigidez na coluna e atrasos nos marcos motores, como sentar ou ficar em pé sem apoio.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Uma distrofia muscular caracterizada por músculos com tônus reduzido (ficam mais moles), fraqueza muscular progressiva e desgaste dos músculos (atrofia), articulações que ficam presas de forma incomum, rigidez na coluna e atrasos nos marcos motores, como sentar ou ficar em pé sem apoio.

Pesquisas ativas
10 ensaios
23 total registrados no ClinicalTrials.gov
Publicações científicas
1.902 artigos
Último publicado: 2026 May

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Europe
Início
Infancy
+ neonatal
🏥
SUS: Cobertura mínimaScore: 20%
Centros em: PA, PR, SC, RS, ES +10
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

💪
Músculos
96 sintomas
🧠
Neurológico
63 sintomas
🦴
Ossos e articulações
43 sintomas
👁️
Olhos
34 sintomas
😀
Face
28 sintomas
❤️
Coração
19 sintomas

+ 191 sintomas em outras categorias

Características mais comuns

Alimentação por gastrostomia na infância
Fraqueza muscular da mão
Comprometimento cognitivo
Alimentação por sonda
Ausência de merosina na fibra muscular
Ceratose pilar
533sintomas
Sem dados (533)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 533 características clínicas mais associadas, ordenadas por frequência.

Alimentação por gastrostomia na infânciaGastrostomy tube feeding in infancy
Fraqueza muscular da mãoHand muscle weakness
Comprometimento cognitivoCognitive impairment
Alimentação por sondaTube feeding
Ausência de merosina na fibra muscularAbsent muscle fiber merosin

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico1.902PubMed
Últimos 10 anos200publicações
Pico202564 papers
Linha do tempo
2026Hoje · 2026🧪 1978Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

33 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant, Autosomal recessive.

TRIP4Activating signal cointegrator 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transcription coactivator which associates with nuclear receptors, transcriptional coactivators including EP300, CREBBP and NCOA1, and basal transcription factors like TBP and TFIIA to facilitate nuclear receptors-mediated transcription (PubMed:10454579, PubMed:25219498). May thereby play an important role in establishing distinct coactivator complexes under different cellular conditions (PubMed:10454579, PubMed:25219498). Plays a role in thyroid hormone receptor and estrogen receptor transactiv

LOCALIZAÇÃO

NucleusCytoplasm, cytosolCytoplasm, cytoskeleton, microtubule organizing center, centrosome

VIAS BIOLÓGICAS (1)
ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA
MECANISMO DE DOENÇA

Spinal muscular atrophy with congenital bone fractures 1

An autosomal recessive neuromuscular disorder characterized by prenatal-onset spinal muscular atrophy, multiple congenital contractures consistent with arthrogryposis multiplex congenita, respiratory distress, and congenital bone fractures.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
32.1 TPM
Artéria tibial
26.3 TPM
Cervix Ectocervix
26.3 TPM
Nervo tibial
25.5 TPM
Skin Sun Exposed Lower leg
24.7 TPM
OUTRAS DOENÇAS (3)
spinal muscular atrophy with congenital bone fractures 1congenital muscular dystrophy-respiratory failure-skin abnormalities-joint hyperlaxity syndromeprenatal-onset spinal muscular atrophy with congenital bone fractures
HGNC:12310UniProt:Q15650
INPP5KInositol polyphosphate 5-phosphatase KDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Inositol 5-phosphatase which acts on inositol 1,4,5-trisphosphate, inositol 1,3,4,5-tetrakisphosphate, phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate (PubMed:10753883, PubMed:16824732). Has 6-fold higher affinity for phosphatidylinositol 4,5-bisphosphate than for inositol 1,4,5-trisphosphate (PubMed:10753883). Negatively regulates assembly of the actin cytoskeleton. Controls insulin-dependent glucose uptake among inositol 3,4,5-trisphosphate phosphatases; ther

LOCALIZAÇÃO

Endoplasmic reticulumCytoplasm

VIAS BIOLÓGICAS (1)
Synthesis of PIPs at the plasma membrane
MECANISMO DE DOENÇA

Muscular dystrophy, congenital, with cataracts and impaired intellectual development

An autosomal recessive form of muscular dystrophy with onset in early childhood and characterized by progressive muscle weakness. Almost all patients also have early-onset cataracts and intellectual disability of varying severity. Some patients have seizures.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
62.3 TPM
Testículo
54.3 TPM
Nervo tibial
52.9 TPM
Tecido adiposo
51.7 TPM
Pulmão
51.4 TPM
OUTRAS DOENÇAS (1)
congenital muscular dystrophy with cataracts and intellectual disability
HGNC:33882UniProt:Q9BT40
B4GAT1Beta-1,4-glucuronyltransferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Beta-1,4-glucuronyltransferase involved in O-mannosylation of alpha-dystroglycan (DAG1) (PubMed:19587235, PubMed:23359570, PubMed:25279697, PubMed:25279699). Transfers a glucuronic acid (GlcA) residue onto a xylose (Xyl) acceptor to produce the glucuronyl-beta-1,4-xylose-beta disaccharide primer, which is further elongated by LARGE1, during synthesis of phosphorylated O-mannosyl glycan (PubMed:25279697, PubMed:25279699). Phosphorylated O-mannosyl glycan is a carbohydrate structure present in alp

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (3)
Keratan sulfate biosynthesisMatriglycan biosynthesis on DAG1Defective LARGE causes MDDGA6 and MDDGB6
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A13

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

OUTRAS DOENÇAS (2)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A13muscular dystrophy-dystroglycanopathy, type A
HGNC:15685UniProt:O43505
SELENONSelenoprotein NDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays an important role in cell protection against oxidative stress and in the regulation of redox-related calcium homeostasis. Regulates the calcium level of the ER by protecting the calcium pump ATP2A2 against the oxidoreductase ERO1A-mediated oxidative damage. Within the ER, ERO1A activity increases the concentration of H(2)O(2), which attacks the luminal thiols in ATP2A2 and thus leads to cysteinyl sulfenic acid formation (-SOH) and SEPN1 reduces the SOH back to free thiol (-SH), thus restor

LOCALIZAÇÃO

Endoplasmic reticulum membrane

MECANISMO DE DOENÇA

Congenital myopathy 3 with rigid spine

An autosomal recessive, slowly progressive muscular disorder apparent from birth or early childhood and characterized by hypotonia, proximal muscle weakness, poor axial muscle strength, scoliosis and neck weakness, and a variable degree of spinal rigidity. Most patients remain ambulatory. Early ventilatory insufficiency may lead to death by respiratory failure. Additional features may include facial muscle weakness, amyotrophy, joint contractures, distal hyperlaxity, pulmonary hypertension with secondary cardiac dysfunction, and insulin resistance in patients with a low BMI. Skeletal muscle biopsy typically shows multiminicores and other abnormal non-specific myopathic findings.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
167.2 TPM
Tireoide
103.6 TPM
Útero
101.6 TPM
Ovário
95.0 TPM
Mama
92.8 TPM
OUTRAS DOENÇAS (5)
rigid spine muscular dystrophy 1congenital fiber-type disproportion myopathydesmin-related myopathy with Mallory body-like inclusionsclassic multiminicore myopathy
HGNC:15999UniProt:Q9NZV5
B3GALNT2UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Beta-1,3-N-acetylgalactosaminyltransferase that synthesizes a unique carbohydrate structure, GalNAc-beta-1-3GlcNAc, on N- and O-glycans. Has no galactose nor galactosaminyl transferase activity toward any acceptor substrate. Involved in alpha-dystroglycan (DAG1) glycosylation: acts coordinately with GTDC2/POMGnT2 to synthesize a GalNAc-beta3-GlcNAc-beta-terminus at the 4-position of protein O-mannose in the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3

LOCALIZAÇÃO

Golgi apparatus membraneEndoplasmic reticulum

VIAS BIOLÓGICAS (1)
DAG1 core M3 glycosylations
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A11

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

OUTRAS DOENÇAS (4)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 11muscular dystrophy-dystroglycanopathy, type Aautosomal recessive non-syndromic intellectual disabilitymuscle-eye-brain disease
HGNC:28596UniProt:Q8NCR0
DPM2Dolichol phosphate-mannose biosynthesis regulatory proteinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Regulates the biosynthesis of dolichol phosphate-mannose (PubMed:10835346). Regulatory subunit of the dolichol-phosphate mannose (DPM) synthase complex; essential for the ER localization and stable expression of DPM1 (PubMed:10835346). Part of the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex that catalyzes the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to phosphatidylinositol and participates in the first step of GPI biosynthesis (PubMed:161628

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Synthesis of dolichyl-phosphate mannoseMaturation of DENV proteinsDefective DPM3 causes DPM3-CDGDefective DPM1 causes DPM1-CDGSynthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1U

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Some CDG1U patients have dystrophic changes seen on muscle biopsy and reduced O-mannosyl glycans on alpha-dystroglycan.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
86.9 TPM
Fibroblastos
64.0 TPM
Próstata
61.1 TPM
Cervix Endocervix
59.8 TPM
Cervix Ectocervix
57.1 TPM
OUTRAS DOENÇAS (1)
congenital muscular dystrophy with intellectual disability and severe epilepsy
HGNC:3006UniProt:O94777
GMPPBMannose-1-phosphate guanylyltransferase catalytic subunit betaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic subunit of the GMPPA-GMPPB mannose-1-phosphate guanylyltransferase complex (PubMed:33986552). Catalyzes the formation of GDP-mannose, an essential precursor of glycan moieties of glycoproteins and glycolipids (PubMed:33986552). Can catalyze the reverse reaction in vitro (PubMed:33986552). Together with GMPPA regulates GDP-alpha-D-mannose levels (PubMed:33986552)

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Synthesis of GDP-mannose
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A14

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with brain anomalies, eye malformations, and profound intellectual disability. The disorder includes a severe form designated as Walker-Warburg syndrome and a less severe phenotype known as muscle-eye-brain disease. MDDGA14 features include increased muscle tone, microcephaly, cleft palate, feeding difficulties, severe muscle weakness, sensorineural hearing loss, cerebellar hypoplasia, ataxia, and retinal dysfunction.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
56.4 TPM
Tireoide
41.5 TPM
Linfócitos
39.6 TPM
Próstata
37.0 TPM
Glândula salivar
32.5 TPM
OUTRAS DOENÇAS (7)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A14autosomal recessive limb-girdle muscular dystrophy type 2Tmuscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B14muscle-eye-brain disease
HGNC:22932UniProt:Q9Y5P6
CRPPAD-ribitol-5-phosphate cytidylyltransferaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Cytidylyltransferase required for protein O-linked mannosylation (PubMed:22522420, PubMed:22522421, PubMed:26687144, PubMed:26923585, PubMed:27130732, PubMed:27601598). Catalyzes the formation of CDP-ribitol nucleotide sugar from D-ribitol 5-phosphate (PubMed:26687144, PubMed:26923585, PubMed:27130732). CDP-ribitol is a substrate of FKTN during the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carboh

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A7

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

OUTRAS DOENÇAS (5)
autosomal recessive limb-girdle muscular dystrophy type 2Umuscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7muscle-eye-brain diseasemuscular dystrophy-dystroglycanopathy, type A
HGNC:37276UniProt:A4D126
RXYLT1Ribitol-5-phosphate xylosyltransferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Acts as a UDP-D-xylose:ribitol-5-phosphate beta1,4-xylosyltransferase, which catalyzes the transfer of UDP-D-xylose to ribitol 5-phosphate (Rbo5P) to form the Xylbeta1-4Rbo5P linkage on O-mannosyl glycan (Probable) (PubMed:27733679, PubMed:29477842). Participates in the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1), which is required for bin

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A10

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

OUTRAS DOENÇAS (2)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 10muscular dystrophy-dystroglycanopathy, type A
HGNC:13530UniProt:Q9Y2B1
COL6A3Collagen alpha-3(VI) chainDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Collagen VI acts as a cell-binding protein

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix

VIAS BIOLÓGICAS (1)
Collagen degradation
MECANISMO DE DOENÇA

Bethlem myopathy 1C

A form of Bethlem myopathy, a slowly progressive muscular dystrophy characterized by joint contractures, most frequently affecting the elbows and ankles, and muscle weakness and wasting involving the proximal and extensor muscles more than the distal and flexor ones. The clinical onset more often occurs in childhood or adulthood, but it can be prenatal with decreased fetal movements or neonatal with hypotonia. The hallmark of Bethlem myopathy is long finger flexion contractures. BTHLM1C inheritance is autosomal dominant.

OUTRAS DOENÇAS (6)
dystonia 27Ullrich congenital muscular dystrophy 1CBethlem myopathy 1Cintermediate collagen VI-related muscular dystrophy
HGNC:2213UniProt:P12111
COL6A1Collagen alpha-1(VI) chainDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Collagen VI acts as a cell-binding protein

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix

VIAS BIOLÓGICAS (2)
Collagen biosynthesis and modifying enzymesCollagen chain trimerization
MECANISMO DE DOENÇA

Bethlem myopathy 1A

A form of Bethlem myopathy, a slowly progressive muscular dystrophy characterized by joint contractures, most frequently affecting the elbows and ankles, and muscle weakness and wasting involving the proximal and extensor muscles more than the distal and flexor ones. The clinical onset more often occurs in childhood or adulthood, but it can be prenatal with decreased fetal movements or neonatal with hypotonia. The hallmark of Bethlem myopathy is long finger flexion contractures. Inheritance can be autosomal dominant or autosomal recessive.

OUTRAS DOENÇAS (5)
Ullrich congenital muscular dystrophy 1ABethlem myopathy 1Aintermediate collagen VI-related muscular dystrophyBethlem myopathy
HGNC:2211UniProt:P12109
POMKProtein O-mannose kinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Protein O-mannose kinase that specifically mediates phosphorylation at the 6-position of an O-mannose of the trisaccharide (N-acetylgalactosamine (GalNAc)-beta-1,3-N-acetylglucosamine (GlcNAc)-beta-1,4-mannose) to generate phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-1,3-N-acetylglucosamine-beta-1,4-(phosphate-6-)mannose). Phosphorylated O-mannosyl trisaccharide is a carbohydrate structure present in alpha-dystroglycan (DAG1), which is required for binding laminin G-like d

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
DAG1 core M3 glycosylations
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A12

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
6.4 TPM
Fibroblastos
5.9 TPM
Cérebro - Hemisfério cerebelar
3.0 TPM
Cerebelo
2.7 TPM
Testículo
2.3 TPM
OUTRAS DOENÇAS (4)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 12limb-girdle muscular dystrophy due to POMK deficiencyobsolete congenital muscular dystrophy with cerebellar involvementmuscular dystrophy-dystroglycanopathy, type A
HGNC:26267UniProt:Q9H5K3
SNUPNSnurportin-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Functions as an U snRNP-specific nuclear import adapter. Involved in the trimethylguanosine (m3G)-cap-dependent nuclear import of U snRNPs. Binds specifically to the terminal m3G-cap U snRNAs

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (1)
snRNP Assembly
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 29

An autosomal recessive form of limb girdle muscular dystrophy, a group of genetically heterogeneous muscular disorders that share proximal muscle weakness as the major attribute. Most limb girdle muscular dystrophies present with elevated creatinine kinase and myopathic electromyographic features. Disease is usually progressive to a variable degree, ranging from minor disability to complete inability to ambulate, and can involve the large proximal muscles, as well as axial and facial muscles. Different disease forms may exhibit skeletal muscle hypertrophy, kyphoscoliosis, and contractures or involve other muscle groups and manifest with distal weakness, cardiomyopathy, dysphagia, and respiratory difficulties. LGMDR29 is characterized by muscle weakness predominantly affecting the proximal lower limbs, although upper limb involvement also occurs. Additional features include joint contractures, spinal abnormalities, and significant restrictive ventilatory dysfunction. In rare cases, central nervous system involvement has been reported, including cataracts, developmental delay, and brain imaging abnormalities.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
40.0 TPM
Nervo tibial
25.2 TPM
Ovário
24.3 TPM
Fallopian Tube
23.7 TPM
Cervix Endocervix
23.4 TPM
OUTRAS DOENÇAS (1)
muscular dystrophy, limb-girdle, autosomal recessive 29
HGNC:HGNC:14245UniProt:O95149
DPM3Dolichol-phosphate mannosyltransferase subunit 3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Stabilizer subunit of the dolichol-phosphate mannose (DPM) synthase complex; tethers catalytic subunit DPM1 to the endoplasmic reticulum

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (4)
Synthesis of dolichyl-phosphate mannoseMaturation of DENV proteinsDefective DPM1 causes DPM1-CDGDefective DPM2 causes DPM2-CDG
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B15

An autosomal recessive, congenital muscular disorder characterized by hyperCKemia, myopathic features observed on muscle biopsy, developmental delay, mildly impaired intellectual development with learning difficulties, epilepsy, and mild white matter abnormalities.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
101.0 TPM
Tireoide
86.4 TPM
Útero
85.8 TPM
Cervix Endocervix
81.3 TPM
Fallopian Tube
79.3 TPM
OUTRAS DOENÇAS (2)
DPM3-congenital disorder of glycosylationmuscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type B, 15
HGNC:3007UniProt:Q9P2X0
ITGA7Integrin alpha-7Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Integrin alpha-7/beta-1 is the primary laminin receptor on skeletal myoblasts and adult myofibers. During myogenic differentiation, it may induce changes in the shape and mobility of myoblasts, and facilitate their localization at laminin-rich sites of secondary fiber formation. It is involved in the maintenance of the myofibers cytoarchitecture as well as for their anchorage, viability and functional integrity. Isoform Alpha-7X2B and isoform Alpha-7X1B promote myoblast migration on laminin 1 an

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (3)
Integrin cell surface interactionsLaminin interactionsECM proteoglycans
MECANISMO DE DOENÇA

Muscular dystrophy congenital due to integrin alpha-7 deficiency

A form of congenital muscular dystrophy. Patients present at birth, or within the first few months of life, with hypotonia, muscle weakness and often with joint contractures.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
340.3 TPM
Aorta
336.7 TPM
Artéria coronária
260.5 TPM
Tecido adiposo
249.3 TPM
Esôfago - Muscular
215.4 TPM
OUTRAS DOENÇAS (2)
congenital muscular dystrophy due to integrin alpha-7 deficiencycongenital fiber-type disproportion myopathy
HGNC:6143UniProt:Q13683
POMGNT1Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Participates in O-mannosyl glycosylation by catalyzing the addition of N-acetylglucosamine to O-linked mannose on glycoproteins (PubMed:11709191, PubMed:27493216, PubMed:28512129). Catalyzes the synthesis of the GlcNAc(beta1-2)Man(alpha1-)O-Ser/Thr moiety on alpha-dystroglycan and other O-mannosylated proteins, providing the necessary basis for the addition of further carbohydrate moieties (PubMed:11709191, PubMed:27493216). Is specific for alpha linked terminal mannose and does not have MGAT3,

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (3)
DAG1 core M1 glycosylationsDAG1 core M2 glycosylationsMatriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3

An autosomal recessive disorder characterized by congenital muscular dystrophy, ocular abnormalities, cobblestone lissencephaly, and cerebellar and pontine hypoplasia. Patients present severe congenital myopia, congenital glaucoma, pallor of the optic disks, retinal hypoplasia, intellectual disability, hydrocephalus, abnormal electroencephalograms, generalized muscle weakness and myoclonic jerks. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
61.9 TPM
Tireoide
61.2 TPM
Brain Spinal cord cervical c-1
57.1 TPM
Testículo
54.0 TPM
Nervo tibial
52.7 TPM
OUTRAS DOENÇAS (8)
muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3retinitis pigmentosa 76autosomal recessive limb-girdle muscular dystrophy type 2O
HGNC:19139UniProt:Q8WZA1
FKTNRibitol-5-phosphate transferase FKTNDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the transfer of a ribitol-phosphate from CDP-ribitol to the distal N-acetylgalactosamine of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1) (PubMed:26923585, PubMed:27194101, PubMed:29477842). This constitutes the first step in the formation of the ribitol 5-phosphate tandem repeat which links the phosphorylated O-mannosyl trisaccharide to the ligan

LOCALIZAÇÃO

Golgi apparatus membraneCytoplasmNucleus

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A4

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
21.9 TPM
Nervo tibial
12.9 TPM
Ovário
12.1 TPM
Útero
10.6 TPM
Cérebro - Hemisfério cerebelar
10.4 TPM
OUTRAS DOENÇAS (8)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4autosomal recessive limb-girdle muscular dystrophy type 2Mmuscular dystrophy-dystroglycanopathy (congenital without intellectual disability), type B4dilated cardiomyopathy 1X
HGNC:3622UniProt:O75072
POMT1Protein O-mannosyl-transferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transfers mannosyl residues to the hydroxyl group of serine or threonine residues. Coexpression of both POMT1 and POMT2 is necessary for enzyme activity, expression of either POMT1 or POMT2 alone is insufficient (PubMed:12369018, PubMed:14699049, PubMed:28512129). Essentially dedicated to O-mannosylation of alpha-DAG1 and few other proteins but not of cadherins and protocaherins (PubMed:28512129)

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Regulation of CDH1 posttranslational processing and trafficking to plasma membraneDAG1 core M1 glycosylationsDAG1 core M3 glycosylationsDAG1 core M2 glycosylationsDefective POMT2 causes MDDGA2, MDDGB2 and MDDGC2
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B1

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with intellectual disability and mild structural brain abnormalities.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
73.9 TPM
Cerebelo
65.0 TPM
Cérebro - Hemisfério cerebelar
61.3 TPM
Pituitária
32.9 TPM
Ovário
27.8 TPM
OUTRAS DOENÇAS (8)
autosomal recessive limb-girdle muscular dystrophy type 2Kmuscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B1muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A1muscle-eye-brain disease
HGNC:9202UniProt:Q9Y6A1
FKRPRibitol 5-phosphate transferase FKRPDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the transfer of a ribitol 5-phosphate from CDP-L-ribitol to the ribitol 5-phosphate previously attached by FKTN/fukutin to the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1) (PubMed:26923585, PubMed:27194101, PubMed:29477842, PubMed:31949166). This constitutes the second step in the formation of the ribose 5-phosphate tandem repeat which links the phos

LOCALIZAÇÃO

Golgi apparatus membraneSecretedCell membrane, sarcolemmaRough endoplasmic reticulumCytoplasm

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A5

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
19.7 TPM
Útero
18.0 TPM
Fibroblastos
17.7 TPM
Tireoide
16.6 TPM
Fallopian Tube
16.5 TPM
OUTRAS DOENÇAS (8)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A5muscular dystrophy-dystroglycanopathy type B5autosomal recessive limb-girdle muscular dystrophy type 2Imuscle-eye-brain disease
HGNC:17997UniProt:Q9H9S5
COL4A1Collagen alpha-1(IV) chainCandidate gene tested inAltamente restrito
FUNÇÃO

Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen Arresten, comprising the C-terminal NC1 domain, inhibits angiogenesis and tumor formation. The C-terminal half is found to possess the anti-angiogenic activity. Specifically inhibits endothelial cell proliferation, migration and tube formation

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix, basement membrane

VIAS BIOLÓGICAS (1)
Collagen degradation
MECANISMO DE DOENÇA

Hereditary angiopathy with nephropathy aneurysms and muscle cramps

The clinical renal manifestations include hematuria and bilateral large cysts. Histologic analysis revealed complex basement membrane defects in kidney and skin. The systemic angiopathy appears to affect both small vessels and large arteries.

OUTRAS DOENÇAS (8)
brain small vessel disease 1 with or without ocular anomaliesautosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndromeretinal arterial tortuositymicroangiopathy and leukoencephalopathy, pontine, autosomal dominant
HGNC:2202UniProt:P02462
POMGNT2Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

O-linked mannose beta-1,4-N-acetylglucosaminyltransferase that transfers UDP-N-acetyl-D-glucosamine to the 4-position of the mannose to generate N-acetyl-D-glucosamine-beta-1,4-O-D-mannosylprotein. Involved in the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1), which is required for binding laminin G-like domain-containing extracellular prote

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
DAG1 core M3 glycosylations
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A8

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
98.5 TPM
Cerebelo
94.9 TPM
Cérebro - Hemisfério cerebelar
94.0 TPM
Ovário
60.0 TPM
Fallopian Tube
58.8 TPM
OUTRAS DOENÇAS (3)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 8muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 8muscular dystrophy-dystroglycanopathy, type A
HGNC:25902UniProt:Q8NAT1
CHKBCholine/ethanolamine kinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Has a key role in phospholipid metabolism, and catalyzes the first step of phosphatidylethanolamine and phosphatidylcholine biosynthesis

LOCALIZAÇÃO

VIAS BIOLÓGICAS (2)
Synthesis of PCSynthesis of PE
MECANISMO DE DOENÇA

Muscular dystrophy, congenital, megaconial type

An autosomal recessive, congenital muscular dystrophy characterized by early-onset muscle wasting, intellectual disability, and dilated cardiomyopathy in half of affected individuals. Some patients may die from cardiomyopathy in the first or second decade of life. Muscle biopsy shows peculiar enlarged mitochondria that are prevalent toward the periphery of the fibers but are sparse in the center.

OUTRAS DOENÇAS (2)
megaconial type congenital muscular dystrophyproximal myopathy with focal depletion of mitochondria
HGNC:1938UniProt:Q9Y259
LMNAPrelamin-A/CDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Lamins are intermediate filament proteins that assemble into a filamentous meshwork, and which constitute the major components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane (PubMed:10080180, PubMed:10580070, PubMed:10587585, PubMed:10814726, PubMed:11799477, PubMed:12075506, PubMed:12927431, PubMed:15317753, PubMed:18551513, PubMed:18611980, PubMed:2188730, PubMed:22431096, PubMed:2344612, PubMed:23666920, PubMed:24741066, PubMed:31434876, PubMed:

LOCALIZAÇÃO

Nucleus laminaNucleus envelopeNucleus, nucleoplasmNucleus matrixNucleus speckle

VIAS BIOLÓGICAS (1)
Initiation of Nuclear Envelope (NE) Reformation
MECANISMO DE DOENÇA

Emery-Dreifuss muscular dystrophy 2, autosomal dominant

A form of Emery-Dreifuss muscular dystrophy, a degenerative myopathy characterized by weakness and atrophy of muscle without involvement of the nervous system, early contractures of the elbows, Achilles tendons and spine, and cardiomyopathy associated with cardiac conduction defects.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
392.7 TPM
Aorta
300.6 TPM
Skin Not Sun Exposed Suprapubic
297.7 TPM
Skin Sun Exposed Lower leg
272.6 TPM
Útero
255.8 TPM
OUTRAS DOENÇAS (23)
restrictive dermopathy 2familial partial lipodystrophy, Dunnigan typedilated cardiomyopathy-hypergonadotropic hypogonadism syndromemandibuloacral dysplasia with type A lipodystrophy
HGNC:6636UniProt:P02545
COL12A1Collagen alpha-1(XII) chainDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Type XII collagen interacts with type I collagen-containing fibrils, the COL1 domain could be associated with the surface of the fibrils, and the COL2 and NC3 domains may be localized in the perifibrillar matrix

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix

VIAS BIOLÓGICAS (3)
Collagen degradationAssembly of collagen fibrils and other multimeric structuresCollagen biosynthesis and modifying enzymes
MECANISMO DE DOENÇA

Ullrich congenital muscular dystrophy 2

A form of Ullrich congenital muscular dystrophy, a disease characterized by generalized muscle weakness and striking hypermobility of distal joints in conjunction with variable contractures of more proximal joints and normal intelligence. Additional findings may include kyphoscoliosis, protruded calcanei, and follicular hyperkeratosis (rough skin). More severely affected patients manifest at birth and never achieve independent ambulation, while patients with milder phenotypes might maintain ambulation into adulthood. UCMD2 is a severe, autosomal recessive form with onset at birth.

OUTRAS DOENÇAS (4)
Ullrich congenital muscular dystrophy 2Bethlem myopathy 2Bethlem myopathyUllrich congenital muscular dystrophy
HGNC:2188UniProt:Q99715
DOK7Protein Dok-7Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Probable muscle-intrinsic activator of MUSK that plays an essential role in neuromuscular synaptogenesis. Acts in aneural activation of MUSK and subsequent acetylcholine receptor (AchR) clustering in myotubes. Induces autophosphorylation of MUSK

LOCALIZAÇÃO

Cell membraneSynapse

MECANISMO DE DOENÇA

Myasthenic syndrome, congenital, 10

A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS10 is an autosomal recessive, post-synaptic form characterized by a typical 'limb girdle' pattern of muscle weakness with small, simplified neuromuscular junctions but normal acetylcholine receptor and acetylcholinesterase function.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
28.4 TPM
Coração - Átrio
27.8 TPM
Cerebelo
21.0 TPM
Músculo esquelético
19.7 TPM
Cérebro - Hemisfério cerebelar
19.5 TPM
OUTRAS DOENÇAS (4)
congenital myasthenic syndrome 10fetal akinesia deformation sequence 3postsynaptic congenital myasthenic syndromefetal akinesia deformation sequence 1
HGNC:26594UniProt:Q18PE1
COL6A2Collagen alpha-2(VI) chainDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Collagen VI acts as a cell-binding protein

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrixMembrane

VIAS BIOLÓGICAS (2)
Collagen biosynthesis and modifying enzymesCollagen chain trimerization
MECANISMO DE DOENÇA

Bethlem myopathy 1B

A form of Bethlem myopathy, a slowly progressive muscular dystrophy characterized by joint contractures, most frequently affecting the elbows and ankles, and muscle weakness and wasting involving the proximal and extensor muscles more than the distal and flexor ones. The clinical onset more often occurs in childhood or adulthood, but it can be prenatal with decreased fetal movements or neonatal with hypotonia. The hallmark of Bethlem myopathy is long finger flexion contractures. Inheritance can be autosomal dominant or autosomal recessive.

OUTRAS DOENÇAS (6)
Ullrich congenital muscular dystrophy 1BmyosclerosisBethlem myopathy 1Bintermediate collagen VI-related muscular dystrophy
HGNC:2212UniProt:P12110
SYNE1Nesprin-1Candidate gene tested inRestrito
FUNÇÃO

Multi-isomeric modular protein which forms a linking network between organelles and the actin cytoskeleton to maintain the subcellular spatial organization. As a component of the LINC (LInker of Nucleoskeleton and Cytoskeleton) complex involved in the connection between the nuclear lamina and the cytoskeleton. The nucleocytoplasmic interactions established by the LINC complex play an important role in the transmission of mechanical forces across the nuclear envelope and in nuclear movement and p

LOCALIZAÇÃO

Nucleus outer membraneNucleusNucleus envelopeCytoplasm, cytoskeletonCytoplasm, myofibril, sarcomereGolgi apparatus

VIAS BIOLÓGICAS (1)
Meiotic synapsis
MECANISMO DE DOENÇA

Spinocerebellar ataxia, autosomal recessive, 8

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR8 is an autosomal recessive form.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
64.7 TPM
Cérebro - Hemisfério cerebelar
59.5 TPM
Ovário
38.9 TPM
Aorta
30.2 TPM
Tireoide
27.1 TPM
OUTRAS DOENÇAS (5)
Emery-Dreifuss muscular dystrophy 4, autosomal dominantautosomal recessive ataxia, Beauce typearthrogryposis multiplex congenita 3, myogenic typeautosomal recessive myogenic arthrogryposis multiplex congenita
HGNC:17089UniProt:Q8NF91
POMT2Protein O-mannosyl-transferase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transfers mannosyl residues to the hydroxyl group of serine or threonine residues. Coexpression of both POMT1 and POMT2 is necessary for enzyme activity, expression of either POMT1 or POMT2 alone is insufficient (PubMed:14699049, PubMed:28512129). Essentially dedicated to O-mannosylation of alpha-DAG1 and few other proteins but not of cadherins and protocaherins (PubMed:28512129)

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Regulation of CDH1 posttranslational processing and trafficking to plasma membraneDAG1 core M1 glycosylationsDAG1 core M3 glycosylationsDAG1 core M2 glycosylationsDefective POMT1 causes MDDGA1, MDDGB1 and MDDGC1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A2

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
59.9 TPM
Pituitária
28.9 TPM
Tireoide
27.7 TPM
Cervix Endocervix
21.2 TPM
Cerebelo
21.2 TPM
OUTRAS DOENÇAS (7)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B2autosomal recessive limb-girdle muscular dystrophy type 2Nmuscle-eye-brain disease
HGNC:19743UniProt:Q9UKY4
LARGE1Xylosyl- and glucuronyltransferase LARGE1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Bifunctional glycosyltransferase with both alpha-1,3-xylosyltransferase and beta-1,3-glucuronyltransferase activities involved in the maturation of alpha-dystroglycan (DAG1) by glycosylation leading to DAG1 binding to laminin G-like domain-containing extracellular proteins with high affinity (PubMed:15661757, PubMed:15752776, PubMed:21987822, PubMed:22223806, PubMed:23125099, PubMed:25279697, PubMed:25279699). Elongates the glucuronyl-beta-1,4-xylose-beta disaccharide primer structure initiated

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B6

A congenital muscular dystrophy associated with profound intellectual disability, white matter changes and structural brain abnormalities. Skeletal muscle biopsies show reduced immunolabeling of alpha-dystroglycan.

EXPRESSÃO TECIDUAL(Ubíquo)
Cólon sigmoide
22.7 TPM
Útero
20.5 TPM
Coração - Ventrículo esquerdo
17.8 TPM
Fallopian Tube
16.4 TPM
Cervix Ectocervix
15.9 TPM
OUTRAS DOENÇAS (5)
muscular dystrophy-dystroglycanopathy type B6muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A6muscle-eye-brain diseasemuscular dystrophy-dystroglycanopathy, type A
HGNC:6511UniProt:O95461
DYSFDysferlinCandidate gene tested inTolerante
FUNÇÃO

Key calcium ion sensor involved in the Ca(2+)-triggered synaptic vesicle-plasma membrane fusion. Plays a role in the sarcolemma repair mechanism of both skeletal muscle and cardiomyocytes that permits rapid resealing of membranes disrupted by mechanical stress (By similarity)

LOCALIZAÇÃO

Cell membrane, sarcolemmaCytoplasmic vesicle membraneCell membraneLate endosome membrane

VIAS BIOLÓGICAS (1)
Smooth Muscle Contraction
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 2

An autosomal recessive degenerative myopathy characterized by weakness and atrophy starting in the proximal pelvifemoral muscles, with onset in the late teens or later, massive elevation of serum creatine kinase levels and slow progression. Scapular muscle involvement is minor and not present at onset. Upper limb girdle involvement follows some years after the onset in lower limbs.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
164.1 TPM
Baço
67.3 TPM
Músculo esquelético
44.4 TPM
Pulmão
30.5 TPM
Cólon sigmoide
23.4 TPM
OUTRAS DOENÇAS (6)
autosomal recessive limb-girdle muscular dystrophy type 2Bdistal myopathy with anterior tibial onsetMiyoshi muscular dystrophy 1autosomal recessive limb-girdle muscular dystrophy
HGNC:3097UniProt:O75923
LAMA2Laminin subunit alpha-2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix, basement membrane

VIAS BIOLÓGICAS (8)
MET activates PTK2 signalingDevelopmental Lineage of Pancreatic Ductal CellsAttachment of bacteria to epithelial cellsLaminin interactionsEGR2 and SOX10-mediated initiation of Schwann cell myelination
MECANISMO DE DOENÇA

Merosin-deficient congenital muscular dystrophy 1A

Characterized by difficulty walking, hypotonia, proximal weakness, hyporeflexia, and white matter hypodensity on MRI.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
116.5 TPM
Nervo tibial
92.9 TPM
Fallopian Tube
80.1 TPM
Artéria coronária
63.2 TPM
Fibroblastos
62.6 TPM
OUTRAS DOENÇAS (2)
congenital merosin-deficient muscular dystrophy 1Amuscular dystrophy, limb-girdle, autosomal recessive 23
HGNC:6482UniProt:P24043
DAG1Dystroglycan 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

The dystroglycan complex is involved in a number of signaling events and processes including laminin deposition and extracellular matrix assembly, acetylcholine receptor clustering, sarcolemmal stability, cell survival, peripheral nerve myelination, nodal structure, cell migration, epithelial polarization, and epithelium branching morphogenesis (By similarity). Required for the formation of photoreceptor ribbon synapses, and long-term maintenance of inhibitory synapses in cerebellar Purkinje cel

LOCALIZAÇÃO

Secreted, extracellular spaceSecreted, extracellular space, extracellular matrix, basement membraneSynapseCell membraneCytoplasm, cytoskeletonNucleus, nucleoplasmCell membrane, sarcolemmaPostsynaptic cell membrane

VIAS BIOLÓGICAS (1)
Formation of the dystrophin-glycoprotein complex (DGC)
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy limb-girdle C9

An autosomal recessive muscular dystrophy showing onset in early childhood, and associated with intellectual disability without structural brain anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
118.7 TPM
Artéria tibial
71.1 TPM
Aorta
69.5 TPM
Esôfago - Muscular
66.9 TPM
Esôfago - Junção
64.7 TPM
OUTRAS DOENÇAS (5)
autosomal recessive limb-girdle muscular dystrophy type 2Pmuscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A9isolated asymptomatic elevation of creatine phosphokinasemuscular dystrophy-dystroglycanopathy, type A
HGNC:2666UniProt:Q14118
BET1BET1 homologDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for vesicular transport from the ER to the Golgi complex (PubMed:34779586). Functions as a SNARE involved in the docking process of ER-derived vesicles with the cis-Golgi membrane (By similarity)

LOCALIZAÇÃO

Endoplasmic reticulum membraneGolgi apparatus, cis-Golgi network membraneGolgi apparatus membrane

VIAS BIOLÓGICAS (2)
COPII-mediated vesicle transportCOPI-mediated anterograde transport
MECANISMO DE DOENÇA

Muscular dystrophy, congenital, with rapid progression

An autosomal recessive congenital disease that manifests with severely progressive muscular dystrophy, and results in death in infancy or early childhood. Clinical features include hypotonia and poor feeding, delayed motor development, progressive weakness and lethargy, and respiratory insufficiency. Some patients may have refractory epilepsy and cataracts.

OUTRAS DOENÇAS (1)
muscular dystrophy, congenital, with rapid progression
HGNC:HGNC:14562UniProt:O15155

Variantes genéticas (ClinVar)

232 variantes patogênicas registradas no ClinVar.

🧬 TRIP4: NM_016213.5(TRIP4):c.1460_1463dup (p.Arg489fs) ()
🧬 TRIP4: NM_016213.5(TRIP4):c.652C>T (p.Arg218Cys) ()
🧬 TRIP4: NM_016213.5(TRIP4):c.1123C>A (p.Pro375Thr) ()
🧬 TRIP4: NM_016213.5(TRIP4):c.1214G>A (p.Arg405His) ()
🧬 TRIP4: NM_016213.5(TRIP4):c.185A>G (p.Gln62Arg) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 9,939 variantes classificadas pelo ClinVar.

994
2485
6460
Patogênica (10.0%)
VUS (25.0%)
Benigna (65.0%)
VARIANTES MAIS SIGNIFICATIVAS
FKRP: NM_024301.5(FKRP):c.836G>A (p.Trp279Ter) [Pathogenic]
CHKB: NM_005198.5(CHKB):c.689_690del (p.Glu230fs) [Pathogenic]
FKTN: NM_001079802.2(FKTN):c.923A>C (p.Gln308Pro) [Uncertain significance]
SELENON: NM_206926.2(SELENON):c.986C>T (p.Pro329Leu) [Uncertain significance]
ITGA7: NM_002206.3(ITGA7):c.2704C>T (p.Leu902Phe) [Uncertain significance]

Vias biológicas (Reactome)

53 vias biológicas associadas aos genes desta condição.

ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA Synthesis of PIPs at the plasma membrane Keratan sulfate biosynthesis Defective LARGE causes MDDGA6 and MDDGB6 Matriglycan biosynthesis on DAG1 DAG1 core M3 glycosylations Synthesis of dolichyl-phosphate mannose Synthesis of glycosylphosphatidylinositol (GPI) Defective DPM1 causes DPM1-CDG Defective DPM3 causes DPM3-CDG Defective DPM2 causes DPM2-CDG Maturation of DENV proteins Synthesis of GDP-mannose Collagen degradation Collagen biosynthesis and modifying enzymes Signaling by PDGF Assembly of collagen fibrils and other multimeric structures Integrin cell surface interactions ECM proteoglycans NCAM1 interactions Collagen chain trimerization snRNP Assembly Laminin interactions Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 DAG1 core M2 glycosylations DAG1 core M1 glycosylations Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2 Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1 Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Fibronectin matrix formation Anchoring fibril formation Crosslinking of collagen fibrils Non-integrin membrane-ECM interactions Scavenging by Class A Receptors Attachment of bacteria to epithelial cells Synthesis of PC Synthesis of PE Meiotic synapsis Nuclear Envelope Breakdown Initiation of Nuclear Envelope (NE) Reformation Breakdown of the nuclear lamina XBP1(S) activates chaperone genes Depolymerization of the Nuclear Lamina Signaling by BRAF and RAF1 fusions Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Smooth Muscle Contraction MET activates PTK2 signaling EGR2 and SOX10-mediated initiation of Schwann cell myelination Formation of the dystrophin-glycoprotein complex (DGC) Developmental Lineage of Pancreatic Ductal Cells Regulation of expression of SLITs and ROBOs COPII-mediated vesicle transport COPI-mediated anterograde transport

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado1
2Fase 21
1Fase 11
·Pré-clínico17
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Distrofia muscular, congênita

Centros de Referência SUS

24 centros habilitados pelo SUS para Distrofia muscular, congênita

Centros para Distrofia muscular, congênita

Detalhes dos centros

Hospital Universitário Prof. Edgard Santos (HUPES)

R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital Infantil Albert Sabin

R. Tertuliano Sales, 544 - Vila União, Fortaleza - CE, 60410-794 · CNES 2407876

Serviço de Referência

Rota
Anomalias CongênitasDeficiência Intelectual

Hospital de Apoio de Brasília (HAB)

AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)

Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital das Clínicas da UFG

Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital Universitário da UFJF

R. Catulo Breviglieri, Bairro - s/n - Santa Catarina, Juiz de Fora - MG, 36036-110 · CNES 2297442

Atenção Especializada

Rota
Anomalias Congênitas

Hospital das Clínicas da UFMG

Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Julio Müller (HUJM)

R. Luis Philippe Pereira Leite, s/n - Alvorada, Cuiabá - MT, 78048-902 · CNES 2726092

Atenção Especializada

Rota
Anomalias Congênitas

Hospital Universitário João de Barros Barreto

R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Lauro Wanderley (HULW)

R. Tabeliao Estanislau Eloy, 585 - Castelo Branco, João Pessoa - PB, 58050-585 · CNES 0002470

Atenção Especializada

Rota
Anomalias Congênitas

Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)

R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Pequeno Príncipe

R. Des. Motta, 1070 - Água Verde, Curitiba - PR, 80250-060 · CNES 3143805

Serviço de Referência

Rota
Anomalias CongênitasDeficiência Intelectual

Hospital Universitário Regional de Maringá (HUM)

Av. Mandacaru, 1590 - Parque das Laranjeiras, Maringá - PR, 87083-240 · CNES 2216108

Atenção Especializada

Rota
Anomalias Congênitas

Hospital de Clínicas da UFPR

R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Pedro Ernesto (HUPE-UERJ)

Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)

Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital São Lucas da PUCRS

Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Clínicas de Porto Alegre (HCPA)

Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário da UFSC (HU-UFSC)

R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da FMUSP

R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Base de São José do Rio Preto

Av. Brg. Faria Lima, 5544 - Vila Sao Jose, São José do Rio Preto - SP, 15090-000 · CNES 2079798

Atenção Especializada

Rota
Anomalias Congênitas

Hospital de Clínicas da UNICAMP

R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas de Ribeirão Preto (HCRP-USP)

R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

UNIFESP / Hospital São Paulo

R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo
Sobre os centros SUS: Estes centros são habilitados pelo Ministério da Saúde como Serviços de Referência em Doenças Raras ou Serviços de Atenção Especializada. O atendimento é pelo SUS, com encaminhamento da rede de atenção básica.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

10 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

23 ensaios clínicos encontrados, 10 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
636 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 636

#1

Pearls & Oy-sters: Use of Short-Acting B-Agonist in DOK7-Related Congenital Myasthenic Syndrome Treatment.

Neurology2026 Apr 14

Three brothers presented in early childhood with nonspecific symptoms progressive weakness since birth and fatigue over the course of their lives; 2 of them also had ptosis. An initial diagnosis of congenital muscular dystrophy was made based on muscle biopsy findings, but clinical review in adulthood and genetic testing led to a diagnosis of DOK7-related congenital myasthenic syndrome. A low-cost treatment with oral albuterol provided subjective and objective improvements in function. Reevaluation of remote diagnoses based on muscle biopsy findings in the setting of readily available genetic panels can lead to a correct diagnosis, and in some cases, treatment that can greatly improve quality of life for patients.

#2

Skipping the Biopsy: Real-World Experience of Whole-Exome Sequencing as First-Tier Testing in Pediatric Muscular Disorders.

International journal of molecular sciences2026 Mar 06

Muscle biopsy has long been regarded as the cornerstone for diagnosing pediatric muscular disorders; however, it is invasive and may be limited by sampling error and inconclusive histopathological findings. This study aimed to evaluate whether whole-exome sequencing (WES) can effectively replace muscle biopsy as a first-line diagnostic approach in children with suspected neuromuscular disorders. Between January 2018 and December 2025, we prospectively enrolled 47 pediatric patients presenting with clinical features suggestive of muscular disorders at a tertiary medical center in Taiwan. The cohort included patients with suspected muscular dystrophies (n = 21), congenital myopathies (n = 23), and multiplex ligation-dependent probe amplification (MLPA)-negative Duchenne muscular dystrophy (DMD; n = 3). All patients underwent WES as the initial diagnostic test without prior muscle biopsy. Trio-based analysis using parental samples was performed in 29.8% of cases. Variant interpretation followed the American College of Medical Genetics and Genomics (ACMG) guidelines. WES identified a definitive molecular diagnosis in 72.3% of patients (34/47). Diagnostic yields varied by subgroup: 100% (3/3) in MLPA-negative DMD, 71.4% (15/21) in muscular dystrophies, and 69.6% (16/23) in congenital myopathies. Pathogenic or likely pathogenic variants were detected in 31 distinct genes, including COL6A1 and COL6A3, which are associated with Ullrich congenital muscular dystrophy. Notably, 58.8% of diagnosed patients (20/34) received molecular diagnoses that differed from their initial clinical impression, encompassing conditions such as ZSWIM6-associated neurodevelopmental disorders, GJB2-related hearing loss, OCRL-associated Lowe syndrome, and various metabolic or syndromic disorders. In all three MLPA-negative DMD cases, WES identified point mutations amenable to mutation-specific therapies. No patient required a muscle biopsy for diagnostic confirmation during the study period. First-tier WES demonstrates high diagnostic utility in pediatric muscular disorders while avoiding invasive muscle biopsy. The high rate of diagnostic reclassification underscores the substantial phenotypic overlap between primary neuromuscular diseases and other neurological or systemic conditions. These findings support the early implementation of genetic testing to enable accurate diagnosis and timely initiation of targeted therapies.

#3

Dual AAV gene therapy using laminin-linking proteins ameliorates muscle and nerve defects in LAMA2-related muscular dystrophy.

Molecular therapy : the journal of the American Society of Gene Therapy2026 Feb 02

Adeno-associated virus (AAV)-mediated gene replacement holds promise for treating genetic diseases but faces challenges due to the limited packaging capacity and potential immune responses to transgene products, especially in patients lacking endogenous protein. LAMA2-related muscular dystrophy (LAMA2 MD), a severe congenital disorder caused by loss of laminin-α2, presents both hurdles: the LAMA2 gene exceeds AAV capacity, and severely affected patients do not produce the native protein. Here, we developed an AAV-based therapy using two engineered linker proteins derived from endogenously expressed components. These linker proteins restore laminin receptor binding and polymerization, enabling reassembly of a functional basement membrane. Dual AAV delivery of the linkers in a severe LAMA2 MD mouse model resulted in robust expression and significant improvements in muscle histology and function. Employing myotropic capsids enabled therapeutic efficacy at lower vector doses. However, muscle-specific targeting unmasked a LAMA2-related peripheral neuropathy. To address this, we expressed one linker under a muscle-specific promoter and the other under a ubiquitous promoter, delivered via AAV9 or AAV8. This approach achieved near-complete phenotypic restoration when administered neonatally and provided significant benefit when given at progressed disease stages. Our strategy offers a mutation-independent, size-compatible, and potentially immune-tolerable treatment for LAMA2 MD with broad clinical potential.

#4

Impact of maternal compensation on developmental phenotypes in a zebrafish model of severe congenital muscular dystrophy.

PLoS genetics2026 Jan

Genetic compensation is a common phenomenon in zebrafish in response to genetic alterations. Differences between genetic and morpholino-mediated zebrafish models of human diseases have led to significant difficulties in phenotypic interpretation and translatability. One form of compensation is the maternal deposit of mRNAs and proteins to the oocyte that supports developmental processes before zygotic genome activation. In this study, we generated a zebrafish model of severe congenital muscular dystrophy (CMD) by targeting protein O-mannose N-Acetylglucosaminyltransferase 2 (pomgnt2), a maternally provided gene that maintains cell-extracellular matrix interactions through glycosylation and leads to congenital muscular dystrophy when mutated. Zygotic knockouts (ZKOs) retain protein function in the first week post fertilization and survive to adulthood, only developing muscle disease later in life. In contrast, maternal-zygotic KOs (MZKOs) generated from ZKO females develop early-onset muscle disease, reduced motor function, neuronal axon guidance deficits, and retinal synapse disruptions recapitulating features of the human presentation. While assessing transcriptional changes linked to disease progression, the availability of embryos obtained from different breeding strategies also allowed for a direct comparison of ZKOs and MZKOs to define the impact of having a KO mother. We found that offspring from a ZKO mother, independently of genotype, show distinct expression patterns from animals obtained from heterozygous breedings. Some of these changes reflect changes in metabolic function, possibly stemming from maternal metabolic disruption. These findings will not only be applicable for other CMD models targeting maternally provided genes, but also provide new insight into modeling disease using maternal-zygotic mutants.

#5

LAMA2 Triple Variant in a Mexican Child with Congenital Muscular Dystrophy.

Annals of Indian Academy of Neurology2026 Mar 07

Publicações recentes

Ver todas no PubMed

📚 EuropePMC943 artigos no totalmostrando 197

2026

Laminin-α2 is required for the maintenance of the myotendinous junction in vivo.

Matrix biology : journal of the International Society for Matrix Biology
2026

Clinico-genetic heterogeneity in Pakistani families affected with muscular dystrophies.

Molecular biology reports
2026

Pearls & Oy-sters: Use of Short-Acting B-Agonist in DOK7-Related Congenital Myasthenic Syndrome Treatment.

Neurology
2026

Skipping the Biopsy: Real-World Experience of Whole-Exome Sequencing as First-Tier Testing in Pediatric Muscular Disorders.

International journal of molecular sciences
2026

LAMA2 Triple Variant in a Mexican Child with Congenital Muscular Dystrophy.

Annals of Indian Academy of Neurology
2026

Expanding the phenotypic spectrum of LAMA2-related disorders: Axonal neuropathy in the absence of muscular dystrophy.

Journal of human genetics
2026

Evaluation of Readthrough Efficiency of Negamycin Derivatives against Nonsense Mutations in Muscular Dystrophy Genes.

Biological &amp; pharmaceutical bulletin
2026

Dual AAV gene therapy using laminin-linking proteins ameliorates muscle and nerve defects in LAMA2-related muscular dystrophy.

Molecular therapy : the journal of the American Society of Gene Therapy
2026

Muscle transcriptome profiling reveals novel molecular pathways and biomarkers in laminin-α2 deficient patients.

Acta neuropathologica communications
2025

LAMA2 variants associated with muscular dystrophy, brain structural abnormalities, and epilepsy: a genotype-phenotype study.

Frontiers in neurology
2026

Impact of maternal compensation on developmental phenotypes in a zebrafish model of severe congenital muscular dystrophy.

PLoS genetics
2025

Tendon Dysfunction in Collagen VI-Related Myopathies: Novel Mechanistic Insights with Therapeutic Potential.

International journal of molecular sciences
2026

The Absence of Collagen VI Reduces Systolic Function but Paradoxically Increases Ca2+ Release in the Rat Heart.

Acta physiologica (Oxford, England)
2025

The Genotypic and Phenotypic Spectrum of GOSR2 Mutations: Clinical and Pathophysiological Insights.

Journal of inherited metabolic disease
2025

The lactate sensor NDRG3 decelerates ER-to-Golgi transport through interaction with the long isoform of syntaxin-5.

Proceedings of the National Academy of Sciences of the United States of America
2025

A novel compound heterozygous variant in LAMA2 gene in a family with merosin-deficient congenital muscular dystrophy.

BMC medical genomics
2025

Ophthalmologic manifestations associated with Fukutin (FKTN) variant subtypes in Korean patients with Fukuyama congenital muscular dystrophy: a single-center retrospective case series.

BMC ophthalmology
2025

Landscape Analysis of COL6A1, COL6A2, and COL6A3 Pathogenic Variants in a Large Italian Cohort Presenting with Collagen VI-Related Myopathies: A Nationwide Report.

Biomolecules
2025

A Sri Lankan boy with Emery-Dreifuss muscular dystrophy 5 presenting during infancy with persistent transaminitis.

BMC pediatrics
2025

Spatial proteomics reveals recombinant human laminin-111 restores adhesion signaling to laminin-α2-deficient muscle.

JCI insight
2025

High Anion Gap Metabolic Acidosis (HAGMA) After Levetiracetam Administration in an 11-Year-Old Boy With Laminin-α2-Deficiency-Associated Muscular Dystrophy and Epilepsy.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
2025

283rd ENMC international workshop: Establishing expert care recommendations for LAMA2-RD: A prototype for the development of congenital muscular dystrophy subtype-specific care guidelines. Hoofddorp, The Netherlands, January 17th-19th 2025.

Neuromuscular disorders : NMD
2025

Precise gene editing of pathogenic Lamin A mutations corrects cardiac disease.

Proceedings of the National Academy of Sciences of the United States of America
2025

Alternative splicing events of three rare variants in CHKB gene causing megaconial congenital dystrophy.

Neurogenetics
2025

[iPS cell-based therapy for muscular disorders].

Rinsho shinkeigaku = Clinical neurology
2025

Corrigendum to "Fukuyama congenital muscular dystrophy: Clinical features and therapeutic advances" [Brain Dev. 47(5) (2025) 104437].

Brain &amp; development
2025

Clinical and Genetic Landscape of Children With Congenital Muscular Dystrophies From North India.

Journal of child neurology
2025

Decoding the pathophysiological role of fukutin in Fukuyama congenital muscular dystrophy.

Brain &amp; development
2025

Evaluation of nutritional status and swallowing functions of children with neuromuscular disordes.

Neuro endocrinology letters
2025

Fukuyama congenital muscular dystrophy: Clinical features and therapeutic advances.

Brain &amp; development
2025

The remarkable effects of the ionized medical water Asea® in 3 boys with Duchenne dystrophy: Three case reports.

World journal of methodology
2025

Broadening the paradigm of laminin α2-related muscular dystrophy: A case of partial merosin deficiency with compound heterozygous variants.

SAGE open medical case reports
2025

Nonrandomized Allocation of Steroid Therapy in Patients With Fukuyama Congenital Muscular Dystrophy: Study Protocol for a Phase II Clinical Trial.

Neuropsychopharmacology reports
2025

Application of the Gross Motor Function Measure in children with conditions other than cerebral palsy: A systematic review.

Developmental medicine and child neurology
2025

A child of congenital muscular dystrophy-dystroglycanopathy with a novel variant in the CRPPA gene: a case report and literature review.

Translational pediatrics
2025

A Novel LAMA2 Mutation (c.7412G>A) Was Found in a Chinese Patient With Congenital Muscular Dystrophy.

Journal of cellular and molecular medicine
2025

Exon-Skipping Using Antisense Oligonucleotides for Laminin-Alpha2-Deficient Muscular Dystrophy.

Methods in molecular biology (Clifton, N.J.)
2025

Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.

Methods in molecular biology (Clifton, N.J.)
2025

An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases.

Methods in molecular biology (Clifton, N.J.)
2025

Anti-myogenic and profibrotic effect of serum from patients affected by muscular laminopathies.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology
2025

Pyridoxine-Dependent Epilepsy Mimicking as Congenital Muscular Dystrophy.

Indian journal of pediatrics
2025

The artificial intelligence challenge in rare disease diagnosis: A case study on collagen VI muscular dystrophy.

Computers in biology and medicine
2025

Diagnosis of Australasian Patients with Neuromuscular Disease: Insights from a Comprehensive Panel Approach.

The Journal of molecular diagnostics : JMD
2025

A Novel COL12A1 Mutation Causes Oral Tissue Abnormalities by Regulating Gingival Fibroblast Function.

Oral diseases
2025

Advancements in two-dimensional nanomaterials for regenerative medicine in skeletal muscle repair.

Materials today. Bio
2025

Myopathic Ehlers-Danlos Syndrome (mEDS) Related to COL12A1: Two Novel Families and Literature Review.

International journal of molecular sciences
2025

[Benefits of ω-3 fatty acids in Duchenne muscular dystrophy].

Revista medica del Instituto Mexicano del Seguro Social
2025

MYL1-Related Congenital Myopathy: Clinical, Genetic and Pathological Insights.

Neuropathology and applied neurobiology
2024

Prenatal Diagnosis of Fukuyama Congenital Muscular Dystrophy by Optical Genomic Mapping in a Chinese Family.

Maternal-fetal medicine (Wolters Kluwer Health, Inc.)
2025

Collablots: Quantification of Collagen VI Levels and Its Structural Disorganisation in Cell Cultures From Patients With Collagen VI-Related Dystrophies.

Neuropathology and applied neurobiology
2025

Orthodontic Treatment and 5-year Follow-up in Skeletal Open Bite Case with Congenital Muscular Dystrophy.

The Bulletin of Tokyo Dental College
2025

A Challenge in Perioperative Anesthetic Management: A Case Report of an Infant With Concurrent Ullrich Congenital Muscular Dystrophy and Pierre Robin Sequence.

Cureus
2025

Atypical Presentation of Congenital Muscular Dystrophy: A LAMA2 Related Muscular Dystrophy.

Journal of child neurology
2025

Variable Ophthalmologic Phenotypes Associated with Biallelic Loss-of-Function Variants in POMGNT1.

International journal of molecular sciences
2025

Founder Variants in the Mexican Population: A Systematic Review.

Archives of medical research
2024

Clinical, Pathologic, and Genetic Spectrum of Collagen VI-Related Disorder in China-A Retrospective Observational Multicenter Study.

Human mutation
2025

Inter- and intra-familial phenotypic variability of autosomal dominant collagen VI related disorder.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Characterization of severe COL6-related dystrophy due to the recurrent variant COL6A1 c.930+189C>T.

Brain : a journal of neurology
2025

Novel CHKB Mutation Causing Megaconial Congenital Muscular Dystrophy: A Case Report from India.

Annals of Indian Academy of Neurology
2025

Targeting Galectin-3 to modulate inflammation in LAMA2-deficient congenital muscular dystrophy.

bioRxiv : the preprint server for biology
2025

Suppressive role of fukutin on cell proliferation in uterine cervical carcinoma in relation to Aurora-A kinase.

Histology and histopathology
2025

Molecular insights into genodermatoses: Genetic findings from 43 patients.

Archives of dermatological research
2025

Urinary prostaglandin D2 and E2 metabolites are elevated with disease severity in patients with Fukuyama congenital muscular dystrophy.

Scientific reports
2025

Novel variant of COL12A1 gene causing neonatal hypotonia and respiratory failure.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

A Spectrum of Pathogenic Variants in the LAMA2 Gene in the Russian Federation.

International journal of molecular sciences
2025

[SELENON-related myopathy with scoliosis and respiratory failure since early childhood diagnosed through reassessment during pediatric-to-adult healthcare transition: a case report].

Rinsho shinkeigaku = Clinical neurology
2025

Congenital muscular dystrophies and myopathies: the leading cause of genetic muscular disorders in eleven Chinese families.

BMC musculoskeletal disorders
2025

Child Neurology: Severe GMPPB-Related Congenital Muscular Dystrophy With Rapidly Progressive Encephalopathy Leading to Infantile Death.

Neurology
2025

An unusual cause of hypertrophic cardiomyopathy in an infant: A case report and brief literature review.

La Tunisie medicale
2025

Holter electrocardiography findings in Fukuyama congenital muscular dystrophy.

Neuromuscular disorders : NMD
2025

Generation of a human induced pluripotent stem cell line (CRICKi021-A) from a patient with Ullrich congenital muscular dystrophy carrying a pathogenic mutation in the COL6A1 gene.

Stem cell research
2025

Systemic inhibition of bone morphogenetic protein 1.3 as a possible treatment for laminin-related congenital muscular dystrophy.

International orthopaedics
2024

Restored Collagen VI Microfilaments Network in the Extracellular Matrix of CRISPR-Edited Ullrich Congenital Muscular Dystrophy Fibroblasts.

Biomolecules
2025

Cross-Sectional Study of the Association Between Plasma Brain Natriuretic Peptide Levels and Left Ventricular Shortening Fraction in Fukuyama Congenital Muscular Dystrophy.

The Tohoku journal of experimental medicine
2024

A Novel Splice Site Variant in COL6A1 Causes Ullrich Congenital Muscular Dystrophy in a Consanguineous Malian Family.

Molecular genetics &amp; genomic medicine
2026

Structural and functional consequences of non-synonymous SNPs within the LAMA2 protein: a molecular dynamics perspective.

Journal of biomolecular structure &amp; dynamics
2024

Acute weakness and elevated creatine kinase levels associated with coxsackievirus infection in LAMA2-related muscular dystrophy.

Neuromuscular disorders : NMD
2024

Immune-Mediated Megaconial Myopathy: A Novel Subtype of Autoimmune Myopathy.

Neurology
2024

A rare homozygous variant of CHKB induced severe cardiomyopathy and a cardiac conduction disorder: a case report.

Frontiers in cardiovascular medicine
2024

A 5-year natural history study in LAMA2-related muscular dystrophy and SELENON-related myopathy: the Extended LAST STRONG study.

BMC neurology
2024

Laminin-α2 chain deficiency in skeletal muscle causes dysregulation of multiple cellular mechanisms.

Life science alliance
2024

Distinct muscle regenerative capacity of human induced pluripotent stem cell-derived mesenchymal stromal cells in Ullrich congenital muscular dystrophy model mice.

Stem cell research &amp; therapy
2024

Clinical and Molecular Profiles of a Cohort of Egyptian Patients with Collagen VI-Related Dystrophy.

Journal of molecular neuroscience : MN
2024

Epilepsy Secondary to Occipital Cobblestone Malformation in an Adult Patient with Merosin-Deficient Congenital Muscular Dystrophy Type 1A.

Acta medica portuguesa
2024

Walker-Warburg syndrome: A case report of congenital muscular dystrophy with hydrocephalus.

Radiology case reports
2024

A Multicenter Cross-Sectional Study of the Swiss Cohort of LAMA2-Related Muscular Dystrophy.

Journal of neuromuscular diseases
2024

An international retrospective early natural history study of LAMA2-related dystrophies.

Journal of neuromuscular diseases
2024

Allele-specific CRISPR-Cas9 editing inactivates a single nucleotide variant associated with collagen VI muscular dystrophy.

Molecular therapy. Nucleic acids
2025

Megaconial congenital muscular dystrophy: Importance of cutaneous features and successful response to ustekinumab.

Pediatric dermatology
2024

Pearls & Oy-sters: Use of Muscle Ultrasound as a Clinical Tool in INPP5K-Related Muscular Dystrophy: A Case Report.

Neurology
2024

COL12A1 Gene Variant and a Review of the Literature: A Case Report of Ullrich Congenital Muscular Dystrophy.

Molecular syndromology
2024

A novel homozygous nonsense variant in COL12A1 causes myopathic Ehlers-Danlos syndrome: A case report and literature review.

Neuropathology and applied neurobiology
2024

Muscle Mass as a Biomarker for Health Status and Function in Pediatric Individuals with Neuromuscular Disabilities: A Systematic Review.

Children (Basel, Switzerland)
2024

Clinical and Genetic Heterogeneity of Nuclear Envelopathy Related Muscular Dystrophies in an Indian Cohort.

Journal of neuromuscular diseases
2024

Compound Heterozygous Variants of GOSR2 Associated With Congenital Muscular Dystrophy and Progressive Myoclonus Epilepsy: A Case Report.

Neurology. Genetics
2024

Characterization of Proteome Changes in Aged and Collagen VI-Deficient Human Pericyte Cultures.

International journal of molecular sciences
2024

Strategies to improve the design of gapmer antisense oligonucleotide on allele-specific silencing.

Molecular therapy. Nucleic acids
2024

Identification of LAMA2 compound heterozygous variants: a case report.

Translational pediatrics
2024

An Extremely Rare LAMA2 Gene Variant c.442C>T (p.Arg148Trp) Causing Late-Onset LAMA2-Related Dystrophy.

Cureus
2024

Phase 1 Open-Label Study of Omigapil in Patients With LAMA2- or COL6-Related Dystrophy.

Neurology. Genetics
2024

Congenital LMNA-Related Muscular Dystrophy in Paediatrics: Cardiac Management in Monozygotic Twins.

International journal of molecular sciences
2024

Optimizing Embryo Collection for Application of CRISPR/Cas9 System and Generation of Fukutin Knockout Rat Using This Method.

Current issues in molecular biology
2024

Lama1 upregulation prolongs the lifespan of the dyH/dyH mouse model of LAMA2-related congenital muscular dystrophy.

Journal of genetics and genomics = Yi chuan xue bao
2024

Genetic profile of Brazilian patients with LAMA2-related dystrophies.

Clinical genetics
2024

A novel deep intronic variant in LAMA2 identified by RNA sequencing.

Neuromuscular disorders : NMD
2024

Feasibility of multimodal therapy for rhabdomyosarcoma in a patient with Fukuyama congenital muscular dystrophy.

Pediatric blood &amp; cancer
2024

Optimized allele-specific silencing of the dominant-negative COL6A1 G293R substitution causing collagen VI-related dystrophy.

Molecular therapy. Nucleic acids
2024

The recurrent deep intronic pseudoexon-inducing variant COL6A1 c.930+189C>T results in a consistently severe phenotype of COL6-related dystrophy: Towards clinical trial readiness for splice-modulating therapy.

medRxiv : the preprint server for health sciences
2024

Allele-specific CRISPR/Cas9 editing inactivates a single nucleotide variant associated with collagen VI muscular dystrophy.

bioRxiv : the preprint server for biology
2024

TRAPPC11-CDG muscular dystrophy: Review of 54 cases including a novel patient.

Molecular genetics and metabolism
2024

Knockdown of INPP5K compromises the differentiation of N2A cells.

Frontiers in molecular neuroscience
2024

Proteomic characterization of human LMNA-related congenital muscular dystrophy muscle cells.

Neuromuscular disorders : NMD
2024

Splicing Switching of Alternative Last Exons Due to a Deletion Including Canonical Polyadenylation Site in COL6A2 Gene Causes Recessive UCMD.

Neurology. Genetics
2024

Collagen VI Deficiency Impairs Tendon Fibroblasts Mechanoresponse in Ullrich Congenital Muscular Dystrophy.

Cells
2023

Mild limb girdle muscular dystrophy R9 phenotype caused by novel compound heterozygous FKRP gene mutation.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology
2024

Genetic blueprint of congenital muscular dystrophies with brain malformations in Egypt: A report of 11 families.

Neurogenetics
2024

Inhibitory CCK+ basket synapse defects in mouse models of dystroglycanopathy.

eLife
2023

Collagen XII-Related Myopathy: An Emerging Spectrum of Extracellular Matrix-Related Myopathy.

Neurology India
2023

Retrospective clinical and genetic analysis of COL6-RD patients with a long-term follow-up at a single French center.

Frontiers in genetics
2023

Assessing the Assisted Six-Minute Cycling Test as a Measure of Endurance in Non-Ambulatory Patients with Spinal Muscular Atrophy (SMA).

Journal of clinical medicine
2024

Expanding the phenotypic and genotypic spectrum of GGPS1 related congenital muscular dystrophy.

American journal of medical genetics. Part A
2023

Spontaneous mutation in the COL6A2 gene causing Ullrich congenital muscular dystrophy type 1 in a Chinese child: A case report.

Medicine
2023

Genetic Patterns of Selected Muscular Dystrophies in the Muscular Dystrophy Surveillance, Tracking, and Research Network.

Neurology. Genetics
2023

A Diagnostic Challenge in an Adolescent with Collagen VI-Related Myopathy and Emotional Disorder-Case Report.

Journal of personalized medicine
2024

Myelin abnormalities in merosin-deficient congenital muscular dystrophy.

Muscle &amp; nerve
2023

Improved efficacy of FKRP AAV gene therapy by combination with ribitol treatment for LGMD2I.

Molecular therapy : the journal of the American Society of Gene Therapy
2024

Skin biopsy findings in megaconial congenital muscular dystrophy with psoriasiform lesions due to variants in CHKB.

Journal of the European Academy of Dermatology and Venereology : JEADV
2023

Cerebrospinal Fluid Proteomic Changes after Nusinersen in Patients with Spinal Muscular Atrophy.

Journal of clinical medicine
2023

Gastrointestinal and nutritional care in pediatric neuromuscular disorders.

World journal of clinical pediatrics
2024

Unexpected partial RNA deletion by two different novel COL6A2 mutations leads to Ullrich congenital muscular dystrophy.

QJM : monthly journal of the Association of Physicians
2023

Novel COL6A3 frameshift variant in American Staffordshire Terrier dogs with Ullrich-like congenital muscular dystrophy.

Journal of veterinary internal medicine
2023

The UCMD-Causing COL6A1 (c.930 + 189C > T) Intron Mutation Leads to the Secretion and Aggregation of Single Mutated Collagen VI α1 Chains.

Human mutation
2023

New Clinical and Immunofluoresence Data of Collagen VI-Related Myopathy: A Single Center Cohort of 69 Patients.

International journal of molecular sciences
2023

Neonatal and infantile hypotonia.

Handbook of clinical neurology
2023

Branchpoints as potential targets of exon-skipping therapies for genetic disorders.

Molecular therapy. Nucleic acids
2023

Autophagy increase in Merosin-Deficient Congenital Muscular Dystrophy type 1A.

European journal of translational myology
2023

Meticulous and Early Understanding of Congenital Cranial Defects Can Save Lives.

Children (Basel, Switzerland)
2023

Early Introduction of Power Mobility Devices for Children with Fukuyama Congenital Muscular Dystrophy and Its Psychological Impact on Caregivers: A Case Report.

Pediatric reports
2023

Whole exome sequencing identifies a novel variant in the COL12A1 gene in a family with Ullrich congenital muscular dystrophy 2.

Molecular biology reports
2023

De novo missense variants in phosphatidylinositol kinase PIP5KIγ underlie a neurodevelopmental syndrome associated with altered phosphoinositide signaling.

American journal of human genetics
2023

Congenital Muscular Dystrophy Due to Merosin Deficiency: Report of a New Mutation.

Cureus
2023

Case report: Novel frameshift mutation in LAMA2 gene causing congenital muscular dystrophy type 1A.

Frontiers in genetics
2023

Limb girdle muscular dystrophy 23 caused by compound heterozygous mutations of LAMA2 gene.

Frontiers in pediatrics
2023

Megaconial congenital muscular dystrophy due to CHKB gene variants, the first report of thirteen Iranian patients.

Neuromuscular disorders : NMD
2023

Merosin-deficient congenital muscular dystrophy type 1a: detection of LAMA2 variants in Vietnamese patients.

Frontiers in genetics
2023

A recurrent homozygous LMNA missense variant p.Thr528Met causes atypical progeroid syndrome characterized by mandibuloacral dysostosis, severe muscular dystrophy, and skeletal deformities.

American journal of medical genetics. Part A
2023

Uniparental disomy for chromosome 1 with POMGNT1 splice-site variant causes muscle-eye-brain disease.

Frontiers in genetics
2023

Homozygous splice variant (c.1741-6G>A) of the COL6A1 gene in three patients with Ullrich congenital muscular dystrophy.

Neuromuscular disorders : NMD
2023

Brain MRI Abnormalities, Epilepsy and Intellectual Disability in LAMA2 Related Dystrophy - a Genotype/Phenotype Correlation.

Journal of neuromuscular diseases
2023

Phenotype Genotype Characterization of FKRP-related Muscular Dystrophy among Indian Patients.

Journal of neuromuscular diseases
2023

Advances in CRISPR/Cas9 Genome Editing for the Treatment of Muscular Dystrophies.

Human gene therapy
2023

Broad spectrum of phenotype and genotype in Korean α-dystroglycan related muscular dystrophy presenting to a tertiary pediatric neuromuscular center.

Neuromuscular disorders : NMD
2023

Alopecia in Patients with Collagen VI-Related Myopathies: A Novel/Unrecognized Scalp Phenotype.

International journal of molecular sciences
2023

Nerve pathology is prevented by linker proteins in mouse models for LAMA2-related muscular dystrophy.

PNAS nexus
2023

LMNA-related muscular dystrophy: Identification of variants in alternative genes and personalized clinical translation.

Frontiers in genetics
2023

Collagen VI-related myopathies: clinical variability, phenotype-genotype correlation and exploratory transcriptome study.

Neuromuscular disorders : NMD
2023

Vemurafenib improves muscle histopathology in a mouse model of LAMA2-related congenital muscular dystrophy.

Disease models &amp; mechanisms
2023

Estimating the Prevalence of LAMA2 Congenital Muscular Dystrophy using Population Genetic Databases.

Journal of neuromuscular diseases
2023

Extracellular Matrix Disorganization and Sarcolemmal Alterations in COL6-Related Myopathy Patients with New Variants of COL6 Genes.

International journal of molecular sciences
2023

Collagen VI in the Musculoskeletal System.

International journal of molecular sciences
2023

Characterization of cardiac involvement in children with LMNA-related muscular dystrophy.

Frontiers in cell and developmental biology
2023

A case of Fukuyama-type congenital muscular dystrophy with acute carnitine deficiency triggered by fever, vomiting, and gastrointestinal bleeding.

Nutrition (Burbank, Los Angeles County, Calif.)
2023

CRISPRa-induced upregulation of human LAMA1 compensates for LAMA2-deficiency in Merosin-deficient congenital muscular dystrophy.

bioRxiv : the preprint server for biology
2023

Preparation of 3D Decellularized Matrices from Fetal Mouse Skeletal Muscle for Cell Culture.

Journal of visualized experiments : JoVE
2023

Unusually severe muscular dystrophy upon in-frame deletion of the dystrophin rod domain and lack of compensation by membrane-localized utrophin.

Med (New York, N.Y.)
2023

Large heterozygous deletion and uniparental disomy masquerading as homozygosity in CHKB gene.

Molecular genetics &amp; genomic medicine
2023

Dual transgene amelioration of Lama2-null muscular dystrophy.

Matrix biology : journal of the International Society for Matrix Biology
2023

Coexistence of Genetic Diseases Is a New Clinical Challenge: Three Unrelated Cases of Dual Diagnosis.

Genes
2023

GDP-Mannose Pyrophosphorylase B (GMPPB)-Related Disorders.

Genes
2023

Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial.

The Lancet. Neurology
2023

Case report: Adult-onset limb girdle muscular dystrophy in sibling pair due to novel homozygous LAMA2 missense variant.

Frontiers in neurology
2023

Assessing the Role of Aquaporin 4 in Skeletal Muscle Function.

International journal of molecular sciences
2023

Bioengineering a miniaturized in vitro 3D myotube contraction monitoring chip to model muscular dystrophies.

Biomaterials
2022

Deletion of POMT2 in Zebrafish Causes Degeneration of Photoreceptors.

International journal of molecular sciences
2022

Integrin α7 Mutations Are Associated With Adult-Onset Cardiac Dysfunction in Humans and Mice.

Journal of the American Heart Association
2023

Antisense oligonucleotide induced pseudoexon skipping and restoration of functional protein for Fukuyama muscular dystrophy caused by a deep-intronic variant.

Human molecular genetics
2023

Exon-Skipping for a Pathogenic COL6A1 Variant in Ullrich Congenital Muscular Dystrophy.

Methods in molecular biology (Clifton, N.J.)
2023

Electroretinogram abnormalities in FKRP-related limb-girdle muscular dystrophy (LGMDR9).

Documenta ophthalmologica. Advances in ophthalmology
2022

Establishment of a PBMC-derived induced pluripotent stem cell (NJUCMi001-A) from a patient with LAMA2-related congenital muscular dystrophy (MDC1A) carrying frameshift deletion c.3367delA in LAMA2 gene.

Stem cell research
2022

The Presentation of Two Unrelated Clinical Cases from the Republic of North Ossetia-Alania with the Same Previously Undescribed Variant in the COL6A2 Gene.

International journal of molecular sciences
2023

Clinical exome sequencing identifies novel compound heterozygous mutations of the POMT2 gene in patients with limb-girdle muscular dystrophy.

International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience
2022

Megaconial congenital muscular dystrophy due to novel CHKB variants: a case report and literature review.

Skeletal muscle
2022

Exercise-Induced Rhabdomyolysis Causing Acute Kidney Injury: A Potential Threat to Gym Lovers.

Cureus
2023

Fetal Presentation of Walker-Warburg Syndrome with Compound Heterozygous POMT2 Missense Mutations.

Fetal and pediatric pathology
2022

Laminin α5_CD239_Spectrin is a candidate association that compensates the linkage between the basement membrane and cytoskeleton in skeletal muscle fibers.

Matrix biology plus
2022

Whole exome sequencing identified a novel LAMA2 frameshift variant causing merosin-deficient congenital muscular dystrophy in a patient with cardiomyopathy, and autism-like behavior.

Neuromuscular disorders : NMD
2023

A novel pathogenic deletion in ISPD causes Walker-Warburg syndrome in a Chinese family.

Genes &amp; genomics
2022

Collagen VI deficiency causes behavioral abnormalities and cortical dopaminergic dysfunction.

Disease models &amp; mechanisms
2022

Congenital Muscular Dystrophy due to POMGNT1 Mutation Presenting as Cardioembolic Stroke.

Annals of Indian Academy of Neurology
2022

[Anesthesia for thoracic surgery in a female patient with Ullrich congenital muscular dystrophy].

Die Anaesthesiologie
2022

Author Correction: Efficacy of steroid therapy for Fukuyama congenital muscular dystrophy.

Scientific reports
2022

Assessment of the upper limb muscles in patients with Fukuyama muscular dystrophy: Noninvasive assessment using visual ultrasound muscle analysis and shear wave elastography.

Neuromuscular disorders : NMD
2022

Cardiac involvement in two rare neuromuscular diseases: LAMA2-related muscular dystrophy and SELENON-related myopathy.

Neuromuscular disorders : NMD
2023

Lack of COL6/collagen VI causes megakaryocyte dysfunction by impairing autophagy and inducing apoptosis.

Autophagy
2022

Autosomal dominant Ullrich congenital muscular dystrophy due to a de novo mutation in COL6A3 gene. A case report.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology
2022

The Use of Autologous Blood Patch in Ullrich Muscular Dystrophy and Recurrent Pneumothorax.

Cureus
2022

[Analysis of clinical features and FKTN gene variant in a child with congenital muscular dystrophy].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
Ver todos os 943 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Distrofia muscular, congênita.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Distrofia muscular, congênita

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Pearls &amp; Oy-sters: Use of Short-Acting B-Agonist in DOK7-Related Congenital Myasthenic Syndrome Treatment.
    Neurology· 2026· PMID 41838965mais citado
  2. Skipping the Biopsy: Real-World Experience of Whole-Exome Sequencing as First-Tier Testing in Pediatric Muscular Disorders.
    International journal of molecular sciences· 2026· PMID 41828661mais citado
  3. Dual AAV gene therapy using laminin-linking proteins ameliorates muscle and nerve defects in LAMA2-related muscular dystrophy.
    Molecular therapy : the journal of the American Society of Gene Therapy· 2026· PMID 41635088mais citado
  4. Impact of maternal compensation on developmental phenotypes in a zebrafish model of severe congenital muscular dystrophy.
    PLoS genetics· 2026· PMID 41533692mais citado
  5. LAMA2 Triple Variant in a Mexican Child with Congenital Muscular Dystrophy.
    Annals of Indian Academy of Neurology· 2026· PMID 41797637mais citado
  6. Laminin-α2 is required for the maintenance of the myotendinous junction in vivo.
    Matrix Biol· 2026· PMID 41856211recente
  7. Clinico-genetic heterogeneity in Pakistani families affected with muscular dystrophies.
    Mol Biol Rep· 2026· PMID 41854802recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:97242(Orphanet)
  2. MONDO:0019950(MONDO)
  3. GARD:9138(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q1321884(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Distrofia muscular, congênita
Compêndio · Raras BR

Distrofia muscular, congênita

ORPHA:97242 · MONDO:0019950
Prevalência
1-9 / 100 000
Herança
Autosomal dominant, Autosomal recessive
CID-11
Ensaios
10 ativos
Início
Infancy, Neonatal
Prevalência
0.0 (Europe)
MedGen
UMLS
C0699743
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades